Allarity Therapeutics, Inc.
$1.25
▲
2.65%
2026-04-21 05:14:00
www.allarity.com
NCM: ALLR
Explore Allarity Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$19.46 M
Current Price
$1.25
52W High / Low
$2.35 / $0.77
Stock P/E
—
Book Value
$0.61
Dividend Yield
—
ROCE
-148.49%
ROE
-1.04%
Face Value
—
EPS
$-0.78
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
7
Beta
0.01
Debt / Equity
14.24
Current Ratio
2.13
Quick Ratio
2.13
Forward P/E
-1.31
Price / Sales
62.78
Enterprise Value
$6.72 M
EV / EBITDA
-0.53
EV / Revenue
21
Rating
None
Target Price
$9.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Silexion Therapeutics Corp | $1.08 | — | $3.63 M | — | -260.98% | 1718.9% | $22.36 / $0.97 | $0.83 |
| 2. | Keros Therapeutics, Inc. | $11.66 | 2.64 | $230.1 M | — | 21.27% | 19.9% | $22.55 / $10.41 | $15.51 |
| 3. | Crescent Biopharma, Inc. | $21.69 | — | $575.8 M | — | -74.74% | -1.61% | $29 / $8.72 | $5.99 |
| 4. | Spruce Biosciences, Inc. | $69.89 | — | $96.45 M | — | -85.04% | -1.09% | $240 / $4.28 | $30.99 |
| 5. | Bio-Techne Corporation | $59.22 | 116.91 | $9.33 B | 0.53% | 10.19% | 3.97% | $72.16 / $46.01 | $12.9 |
| 6. | Liminatus Pharma, Inc. | $0.22 | — | $9.83 M | — | 30.51% | — | $33.66 / $0.16 | $-0.06 |
| 7. | Ovid Therapeutics Inc. | $2.89 | — | $381.12 M | — | -29.75% | -17.51% | $3.1 / $0.27 | $1 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.32 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.92 M | -2.52 M | -4.13 M | -3.04 M | -7.32 M | — |
| Net Profit | -3.37 M | -2.81 M | -2.32 M | -2.73 M | -7.45 M | — |
| EPS in Rs | -0.21 | -0.18 | -0.15 | -0.17 | -0.47 | -7.71 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.32 M | 0 M | 0 M | 0 M |
| Operating Profit | -12.61 M | -17.54 M | -17.13 M | -16.89 M |
| Net Profit | -11.23 M | -24.52 M | -11.9 M | -16.06 M |
| EPS in Rs | -0.71 | -1.55 | -0.75 | -1.02 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 18.26 M | 22.65 M | 11.86 M | 14.54 M |
| Total Liabilities | 8.43 M | 10.84 M | 14.61 M | 12.65 M |
| Equity | 9.83 M | 11.81 M | -2.75 M | 1.89 M |
| Current Assets | 17.93 M | 22.34 M | 1.97 M | 4.97 M |
| Current Liabilities | 8.43 M | 10.84 M | 14.17 M | 11.22 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -14.82 M | -17.35 M | -12.74 M | -16.82 M |
| Investing CF | -0.01 M | -0.3 M | 0 M | 0.79 M |
| Financing CF | 10.65 M | 36.79 M | 10.99 M | -1.31 M |
| Free CF | -14.83 M | -17.65 M | -12.74 M | -16.84 M |
| Capex | -0.01 M | -0.3 M | — | -0.02 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -105.99% | 25.89% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-09-11 | 1:0.0333333 |
| 2024-04-09 | 1:0.05 |
| 2023-06-29 | 1:0.025 |
| 2023-03-27 | 1:0.0285714 |